Key facts
- RheumaGen’s last known valuation is $37.1M (Jan 2025).
- It has raised $15.3M across 4 recorded rounds; the latest was Seed Round ($700K) in Apr 2024.
- Notable investors include SPRIM Global Investments, Colorado Venture Capital Authority, Vida Biomedical, William Taylor Nominees.
- RheumaGen has filed 4 Form Ds with the SEC since 2022, most recently Apr 2024 ($4.9M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for RheumaGen
Funding rounds
4 roundsAbout RheumaGen
Operator of a cell and gene therapy company intended to revolutionize the field of autoimmunity. The company's gene-editing technology is used to cure rheumatoid arthritis (RA) and other autoimmune diseases like multiple sclerosis, celiac, and ankylosing spondylitis, providing healthcare professionals with treatment for refractory rheumatoid arthritis.
- Sector
- Healthcare
- HQ
- Aurora, CO, United States
- Founded
- 2019
- Employees
- 6
- Website
- rheumagen.com/
- Ownership
- Privately Held (backing)
RheumaGen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RheumaGen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RheumaGen in its N-PORT filings yet. We sweep new filings monthly.